Skip to main content

ChemoCentryx receives FDA oProducts development grant for orally administered complement 5a receptor inhibitor CCX168

 

Clinical courses

ChemoCentryx, Inc., announced that the U.S. Food and Drug Administration (FDA) has awarded the Company a one-year grant of $500,000 to assist in the clinical development of CCX168, the Company's lead drug candidate for the treatment of patients with anti-neutrophil cytoplasmic antibody (ANCA) -associated vasculitis, or AAV. CCX168 is an orally-administered small molecule that is a selective inhibitor of the complement C5a receptor, or C5aR.

The goal of the FDA's Orphan Products Development grant program is to support the clinical development of products for use in rare diseases or conditions where no current therapy exists or where the proposed product will be superior to the existing therapy.

FDA provides grants for clinical studies on safety and/or effectiveness that will either result in, or substantially contribute to, market approval of these products.

<< Pharma News

Subscribe to PharmaTutor News Alerts by Email >>